Theme stage · maturing
Medtech stocks to watch · November 2026.
As of 15 November 2026
Note of : Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…
Note of : Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook.
Research view: more likely to lag the S&P 500. Note of : OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth.
Note of : Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback.
Note of : Vericel's knee-cartilage implant MACI is growing above 20% a year and the 5 November 2026 report raised 2026 revenue guidance to $344–346 million.
“3 months” is the stock's market price change over the last three months, not a FrontierPicks return. The "3 months" column is the stock's 3-month price move, one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it.
How this page is built
These are the names FrontierPicks researches in the medtech stocks theme, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closing prices, through the last completed session; the rest follow by the research's conviction, highest first. The research decides which stocks belong to each theme; this one currently reads as maturing: still rising, more slowly.
Questions
- What medtech stocks does FrontierPicks cover?
- As of 15 November 2026, the medtech stocks FrontierPicks researches are led by AXGN, GKOS, KIDS, ENOV, each with a dated research note. Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first.
- Is the medtech stocks theme accelerating or slowing?
- FrontierPicks reads this theme as maturing (still rising, more slowly) as of 15 November 2026. Mid-cap device makers have moved up on product launches and clinical news. OrthoPediatrics (KIDS) began the full commercial launch of its VerteGlide spinal system on 9 November 2026, and Axogen (AXGN) reported early clinical outcomes in prostate nerve reconstruction the same day. Prices are still rising, with Axogen up 57.0% and Glaukos (GKOS) up 48.4% over one month, but the rest of the news is conference appearances rather than new results. Vericel (VCEL) joined the group after Truist raised its target to $65 on 9 November 2026 and Stephens raised its target to $68 on 10 November 2026.
- How does FrontierPicks rank medtech stocks?
- Names in the latest top-50 momentum scan come first, ordered by composite momentum score; the rest follow by the research's conviction, highest first. The full method is on the methodology page.
Related
As of 15 November 2026